American Heart Journal
Volume 154, Issue 1 , Pages 3-11, July 2007

Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs

  • Steven R. Steinhubl, MD

      Affiliations

    • Gill Heart Institute, University of Kentucky, Lexington, KY
    • Corresponding Author InformationReprint requests: Steven R. Steinhubl, MD, The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky College of Medicine, 900 S. Limestone St., 326 C. T. Wethington Bldg., Lexington, KY 40536-0284.
  • ,
  • Adnan Kastrati, MD

      Affiliations

    • Deutsches Herzzentrum, Technische Universitat, Munich, Germany
  • ,
  • Peter B. Berger, MD

      Affiliations

    • Geisinger Medical Center, Danville, PA

Received 26 January 2007; accepted 1 April 2007. published online 23 May 2007.

Background

This review compares and contrasts the various criteria used to characterize bleeding (particularly major bleeding) during recent studies of antithrombotic therapies in acute coronary syndromes (ACSs) and/or percutaneous coronary intervention (PCI).

Methods

This review includes an analysis of recent large randomized clinical trials (published between January 2000 and September 2006; n > 3000 patients) evaluating antithrombotic drugs in patients with ACS or patients undergoing PCI who were identified using Medline searches.

Results

Bleeding has been shown to correlate with patient mortality and major cardiovascular events. Different definitions of bleeding, other than Thrombolysis In Myocardial Infarction or Global Utilization of Streptokinase and t-PA for Occluded coronary arteries bleeding criteria, were used in 9 of the 13 randomized trials that were identified and enrolled over 178,000 patients in total. These definitions overlapped to a degree but differed substantially. Bleeding rates according to several bleeding criteria within one trial illustrate that different bleeding definitions can lead to markedly different conclusions about the safety of an antithrombotic regimen. The shift toward identifying therapies that specifically attempt to reduce bleeding while maintaining efficacy at reducing ischemic complications increases the need of standardized bleeding definitions.

Conclusions

A task force should be initiated to formulate an internationally accepted, meaningful, and standardized approach for reporting bleeding events. A fixed definition may not work for all disease states throughout ACS and PCI. Rather, a predefined scale of bleeding can be proposed, which moves from a more liberal definition of bleeding for elective PCI to a more conservative definition in other settings such as rescue angioplasty.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosures: Dr Steinhubl received research support from and served as a consultant for Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company and served as a consultant for AstraZeneca. Doctor Berger received consulting and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Johnson & Johnson, Genentech, Guilford, Arginox, Schering-Plough, and Boston Scientific and is the medical director and owns equity in Lumen. Doctor Kastrati received lecture fees from Bristol-Myers Squibb, Lilly, and Sanofi-Aventis.

 Disclosures: Financial and editorial support for this publication has been provided by Sanofi-Aventis US Inc.

PII: S0002-8703(07)00287-6

doi:10.1016/j.ahj.2007.04.009

American Heart Journal
Volume 154, Issue 1 , Pages 3-11, July 2007